BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 6861163)

  • 1. Vincristine in advanced bladder cancer: a European organization for research on treatment of cancer (EORTC) phase II study.
    Richards B; Newling D; Fossa S; Bastable JR; Denis L; Jones WB; de Pauw M
    Cancer Treat Rep; 1983 Jun; 67(6):575-7. PubMed ID: 6861163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination chemotherapy for metastatic urinary bladder cancer with 5-FU, vincristine, bleomycin, cyclophosphamide, mitomycin, and methotrexate.
    Kubota Y; Shuin T; Miura T; Moriyama M; Fukushima S; Shiozaki H; Ooshima H
    Cancer Treat Rep; 1984 Sep; 68(9):1167-8. PubMed ID: 6206946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II study of carboplatin in metastatic transitional cell carcinoma of the bladder (a report of the Medical Research Council Working Party on Urological Cancer, Subgroup in Advanced Bladder Cancer).
    Eur J Cancer Clin Oncol; 1987 Apr; 23(4):375-7. PubMed ID: 3301367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium.
    Sweeney CJ; Roth BJ; Kabbinavar FF; Vaughn DJ; Arning M; Curiel RE; Obasaju CK; Wang Y; Nicol SJ; Kaufman DS
    J Clin Oncol; 2006 Jul; 24(21):3451-7. PubMed ID: 16849761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant chemotherapy for invasive urothelial cancer: experience with a methotrexate, vincristine, cisplatin, cyclophosphamide, adriamycin and bleomycin (MVP-CAB) regimen: a preliminary report.
    Gohji K; Higuchi A; Maruyama S; Minayoshi K; Fujii A; Itoh N; Hasunuma Y; Tanaka H; Izumi T
    Jpn J Clin Oncol; 1993 Oct; 23(5):291-8. PubMed ID: 7693990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of amsacrine (AMSA) in previously treated patients with advanced transitional cell carcinoma of the urothelium: a National Bladder Cancer Collaborative Group A study.
    Trump DL; Loening S; Ahmed SW; Wajsman Z
    Cancer Treat Rep; 1983 Sep; 67(9):845-6. PubMed ID: 6688377
    [No Abstract]   [Full Text] [Related]  

  • 7. [Arterial infusion chemotherapy for patients with advanced and moderately advanced cancer of urinary bladder].
    Li Q; Xu X; Liu J
    Zhonghua Zhong Liu Za Zhi; 1998 Jul; 20(4):308-9. PubMed ID: 10920993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Results of the phase II EORTC 22971 trial evaluating combined accelerated external radiation and chemotherapy with 5FU and cisplatin in patients with muscle invasive transitional cell carcinoma of the bladder.
    Poortmans PM; Richaud P; Collette L; Ho Goey S; Pierart M; Van Der Hulst M; Bolla M;
    Acta Oncol; 2008; 47(5):937-40. PubMed ID: 18568488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravesical RTNF therapy of superficial bladder cancer. A phase I study of recombinant tumor necrosis factor administered intravesically to patients with superficial bladder cancer.
    Grampsas SA; Kahn K; Crawford ED
    Online J Curr Clin Trials; 1994 Mar; Doc No 117():[4845 words; 36 paragraphs]. PubMed ID: 8136939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is there a therapeutic role for post-chemotherapy retroperitoneal lymph node dissection in metastatic transitional cell carcinoma of the bladder?
    Sweeney P; Millikan R; Donat M; Wood CG; Radtke AS; Pettaway CA; Grossman HB; Dinney CP; Swanson DA; Pisters LL
    J Urol; 2003 Jun; 169(6):2113-7. PubMed ID: 12771730
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methotrexate-paclitaxel-epirubicin-carboplatin (M-TEC) combination chemotherapy in patients with advanced bladder cancer: an open label phase II study.
    Tsavaris N; Kosmas C; Skopelitis H; Dimitrakopoulos A; Kopterides P; Bougas D; Stravodimos K; Mitropoulos D; Alamanis C; Giannopoulos A
    J Chemother; 2005 Aug; 17(4):441-8. PubMed ID: 16167525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overview of bladder cancer trials in the European Organization for Research and Treatment.
    de Wit R;
    Cancer; 2003 Apr; 97(8 Suppl):2120-6. PubMed ID: 12673705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapy of metastatic bladder cancer.
    Yagoda A
    Cancer; 1980 Apr; 45(7 Suppl):1879-88. PubMed ID: 7189443
    [No Abstract]   [Full Text] [Related]  

  • 14. Phase I trial of paclitaxel, carboplatin, and methotrexate with granulocyte colony-stimulating factor and leucovorin in advanced transitional cell carcinoma.
    Edelman MJ; Meyers FJ; Houston J; Lauder I
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-68-S15-71. PubMed ID: 9346226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 5-Fluorouracil and interferon-alpha in chemotherapy refractory bladder carcinoma: an effective regimen.
    Logothetis CJ; Hossan E; Recondo G; Sella A; Ellerhorst J; Kilbourn R; Zukiwski A; Amato R
    Anticancer Res; 1994; 14(3B):1265-9. PubMed ID: 8067694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence for a schedule-dependent deleterious interaction between paclitaxel, vinblastine and cisplatin (PVC) in the treatment of advanced transitional cell carcinoma.
    Mulatero C; McClaren BR; Mason M; Oliver RT; Gallagher CJ
    Br J Cancer; 2000 Dec; 83(12):1612-6. PubMed ID: 11104554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment with low-dose interferon-alpha restores the balance between matrix metalloproteinase-9 and E-cadherin expression in human transitional cell carcinoma of the bladder.
    Slaton JW; Karashima T; Perrotte P; Inoue K; Kim SJ; Izawa J; Kedar D; McConkey DJ; Millikan R; Sweeney P; Yoshikawa C; Shuin T; Dinney CP
    Clin Cancer Res; 2001 Sep; 7(9):2840-53. PubMed ID: 11555602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radiotherapy plus fifth day carboplatin in locally advanced bladder cancer.
    Radosević-Jelić L; Pekmezović T; Borkovacki R; Marković V
    Neoplasma; 1995; 42(4):203-6. PubMed ID: 7659187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I/II trial of transurethral surgery combined with concurrent cisplatin, 5-fluorouracil and twice daily radiation followed by selective bladder preservation in operable patients with muscle invading bladder cancer.
    Zietman AL; Shipley WU; Kaufman DS; Zehr EM; Heney NM; Althausen AF; McGovern FJ
    J Urol; 1998 Nov; 160(5):1673-7. PubMed ID: 9783929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiotensin-II combined intra-arterial chemotherapy for locally advanced bladder cancer: a case series study at a single institution.
    Shimabukuro T; Nakamura K; Uchiyama K; Tei Y; Aoki A; Naito K
    Hinyokika Kiyo; 2006 Feb; 52(2):99-105. PubMed ID: 16541762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.